Showing Results for
From:PLoS ONE (Vol. 14, Issue 7) Peer-ReviewedBackground Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting 'recent' HIV infection in cross-sectional...
From:PLoS ONE (Vol. 6, Issue 7) Peer-ReviewedBackground Federal guidelines now recommend supplemental HIV RNA testing for persons at high risk for acute HIV infection. However, many rapid HIV testing sites do not include HIV RNA or p24 antigen testing due to...
From:Journal of Infectious Diseases (Vol. 216, Issue 1) Peer-ReviewedCitation Only
From:PLoS ONE (Vol. 4, Issue 12) Peer-ReviewedAuthor(s): Shelley N. Facente 1,*, Teri Dowling 1, Eric Vittinghoff 2, Deanna L. Sykes 3, Grant N. Colfax 1 Introduction In June of 2004, the OraQuick ADVANCE ® Rapid HIV-1/2 Antibody Test (OraSure Technologies,...
From:PLoS ONE (Vol. 13, Issue 7) Peer-ReviewedAuthor(s): Shelley N. Facente, Eduard Grebe, Katie Burk, Meghan D. Morris, Edward L. Murphy, Ali Mirzazadeh, Aaron A. Smith, Melissa A. Sanchez, Jennifer L. Evans, Amy Nishimura, Henry F. Raymond, on behalf of End Hep C...
From:PLoS ONE (Vol. 13, Issue 4) Peer-ReviewedBackground Initiated in 2016, End Hep C SF is a comprehensive initiative to eliminate hepatitis C (HCV) infection in San Francisco. The introduction of direct-acting antivirals to treat and cure HCV provides an...
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it